Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

OpportunityAnalyzer: Myasthenia Gravis Industry Trend, Growth, Opportunity Analysis and Forecasts to 2024

(Medical-NewsWire.com, September 12, 2015 ) Myasthenia gravis is an autoimmune disease affecting the nervous system . While myasthenia gravis is a rare disease it is considered to be the most common neuromuscular disorder and presents itself as a weakness of the muscles. In the majority of patients the disease is initially localized and limited to the eye muscles causing a drooping of the eyelid and double vision. The majority of patients progress to a more severe and generalized form where the disease spreads to other muscles such as bulbar limb and respiratory muscles. Weakness of the respiratory muscles can lead to shortness of breath or in more severe cases it can lead to the patients requiring assisted ventilation. A worsening of myasthenia gravis of this sort is referred to as myasthenia crisis and is a life threatening condition which typically occurs within the first two years after myasthenia gravis onset.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=sample&repid=354567

Highlights

Key Questions Answered

- The myasthenia gravis market has been dominated by short and long-term-immunosuporessants and acetylcholinesterase inhibitors in the last decades. New classes of drugs are anticipated the reach the market within the forecast period. How will these drugs change the myasthenia gravis market? What impact will they have on the market size?
- The current late stage myasthenia gravis pipeline is dominated by monoclonal antibodies. Which monoclonal antibody will have the biggest impact on the market? What strategies are developers undertaking to penetrate this highly generic market? Will the new drugs fulfil any unmet needs?
- Population aging is occurring in almost all countries worldwide particularly in the 7MM. This is expected to have a significant impact on the prevalence of myasthenia gravis. How will epidemiological changes impact the growth of the future market?

Key Findings

- The main driver of growth in the myasthenia gravis market will be the introduction of monoclonal antibodies over the forecast period. The increase in prevalence will support the market growth and a high level of unmet needs will insure that the market remains interesting in the future.
- The biggest barrier for growth in the myasthenia gravis market are anticipated difficulties for the reimbursement of monoclonal antibodies. Furthermore the myasthenia gravis market is dominated by generics and off-label drugs limiting treatment cost for patients who have an acceptable level of disease control.
- The largest unmet needs in myasthenia gravis is a targeted steroid sparing therapy. Approximately 10% of patients are currently treatment refractory and urgently need new treatment options. Patients currently treated with steroids also would benefit from treatment regimen additions.

Browse All Reports in Pharmaceutical Category @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Scope

- Overview of myasthenia gravis including epidemiology etiology pathophysiology symptoms diagnosis and treatment guidelines.
- Annualized myasthenia gravis a market revenue annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include market characterization unmet needs R&D and clinical trials assessment late stage clinical trial analysis and implications for the myastenia gravis therapeutics market.
- Pipeline analysis: focus on the late-stage pipeline myasthenia gravis drugs discussing emerging trends as well as overview of earlier phase drugs.
- Analysis of the current and future market competition in the global myasthenia gravisa therapeutics market. Insightful review of the key industry drivers restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global myasthenia gravis therapeutics market.
- Drive revenues by understanding the key trends innovative products and technologies market segments and companies likely to impact the global myasthenia gravis therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global myasthenia gravis therapeutics market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations investments and strategic partnerships.

Table of Contents
1.1 List of Tables 13
1.2 List of Figures 14
2 Introduction 15
2.1 Catalyst 15
2.2 Related Reports 15
2.3 Upcoming Reports 16
3 Disease Overview 17
3.1 Etiology and Pathophysiology 17
3.1.1 The Complement System and Myasthenia Gravis 18
3.1.2 B-Cells and Myasthenia Gravis 19
3.1.3 Thymoma and Thymectomy 19
3.1.4 Mechanisms of Action of Current and Future Myasthenia Gravis Treatments 20
3.2 Myasthenic Crisis and Other Symptoms 20
3.3 Diagnostic Criteria 21
3.3.1 MGFA and Osserman Classification Systems 21
3.3.2 Diagnostic Tools 23
3.3.3 Treatment Guidelines 24
4 Epidemiology 26
4.1 Disease Background 26
4.2 Risk Factors and Comorbidities 26
4.3 Global Trends 28
4.4 Forecast Methodology 29
4.4.1 Sources Used 31
4.4.2 Sources Not Used 34
4.4.3 Forecast Assumptions and Methods 35
4.5 Epidemiological Forecast of Myasthenia Gravis (2014-2024) 38
4.5.1 Diagnosed Prevalent Cases of Myasthenia Gravis 38
4.5.2 Age-Specific Diagnosed PrevaIent Cases of Myasthenia Gravis 40
4.5.3 Sex-Specific Diagnosed Prevalent Cases of Myasthenia Gravis 41
4.5.4 Age-Standardized Diagnosed Prevalence of Myasthenia Gravis 43
4.5.5 Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Class 44
4.6 Discussion 45
4.6.1 Epidemiological Forecast Insight 45
4.6.2 Limitations of the Analysis 46
4.6.3 Strengths of the Analysis 46

For Market Research Latest Reports Visit @ http://www.researchmoz.us/latest-report.html

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/

Researchmoz Global Pvt.Ltd

Researchmoz

+1-518-621-2074

sales@researchmoz.us

Source: EmailWire.Com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC